Bank of America’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bank of America’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-52,600	Closed	-$2.13M	–	7449
2016 Q1	$2.13M	Buy	+52,600	New	+$3.34M	﹤0.01%	3509

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Bank of America's EGRX Position: Q4 2024 in Review

Bank of America sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 51,006 shares — an estimated $190K sold.

Bank of America first reported a position in EGRX in Q2 2014 and held it in 39 quarters. The position peaked at $9.03M in Q1 2023. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

Bank of America reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
Bank of America sold 51,006 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $190K.
Bank of America first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 39 quarters.
Bank of America's Eagle Pharmaceuticals, Inc. position peaked at $9.03M in Q1 2023.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.